Dysregulation of Epstein-Barr virus (EBV)-specific cellular immunity has been hypothesised as one of the contributing factors in the pathogenesis of systemic lupus erythematosus (SLE). Lupus nephritis is a major risk factor for overall morbidity in SLE. Immune-based strategies directed to EBV have been proposed as potential therapeutic strategy for SLE and lupus nephritis.
| Authors | Ranganathan, D; Leibowitz, S; John, GT; Neller, MA; Ambalathingal, GR; Beagley, L; Panikkar, A; Best, S; Raju, J; Reddiex, H; Ratanjee, S; Ng, MSY; Smith, C; Khanna, R |
|---|---|
| Journal | Clinical & translational immunology |
| Pages | e70015 |
| Volume | 13 |
| Date | 19/12/2024 |
| Grant ID | |
| Funding Body | |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1002/cti2.70015 |